Rucaparib in recurrent ovarian cancer: Real-world experience from the rucaparib early access programme in Spain – A GEICO study
Số trang: 10
Loại file: pdf
Dung lượng: 1.39 MB
Lượt xem: 10
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Recurrent ovarian cancer PARP inhibitor ADP-ribose Maintenance therapy Therapeutic alternativesGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 117 0 0 -
12 trang 92 0 0
-
19 trang 74 0 0
-
17 trang 62 0 0
-
9 trang 40 0 0
-
12 trang 37 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0